PRCT PROCEPT BioRobotics Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1588978 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.5%
TTM net income YoY-35.8%
TTM EPS YoY-32.0%
Revenue 3-yr CAGR44.7%
Net income 3-yr CAGR—
Margins
Gross margin64.7%
Operating margin-33.6%
Net margin-32.6%
FCF margin-24.1%
EBITDA margin-31.3%
Returns
ROE-32.4%
ROA-23.3%
ROIC (approx.)-62.4%
Asset turnover0.72x
Leverage & solvency
Liabilities / assets30.6%
Debt / equity0.16x
Current ratio5.89x
Interest coverage-34.73x
Cash quality & payout
Operating cash flow / net income0.67x
Accruals ratio-7.7%
Payout ratio—
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $308.05M | $224.50M |
| Cost of revenue | $111.83M | $87.40M |
| Gross profit | $196.23M | $137.10M |
| R&D expense | $71.28M | $62.30M |
| SG&A expense | $228.81M | $171.41M |
| Operating income | -$103.86M | -$96.61M |
| Interest expense | $3.59M | $4.18M |
| Pretax income | -$95.38M | -$91.05M |
| Income tax | $190,000 | $368,000 |
| Net income | -$95.57M | -$91.41M |
| EBITDA | -$97.47M | -$91.38M |
| EPS (basic) | -1.72 | -1.75 |
| EPS (diluted) | -1.72 | -1.75 |
| Weighted avg. shares (diluted) | 55.54M | 52.12M |
| Banking | ||
| Provision for credit losses | — | $840,000 |
| Balance sheet | ||
| Cash & equivalents | $286.50M | $336.76M |
| Receivables | $83.53M | $83.50M |
| Inventory | $70.69M | $56.17M |
| Current assets | $450.38M | $481.84M |
| PP&E, net | $30.40M | $26.71M |
| Total assets | $508.08M | $534.02M |
| Current liabilities | $65.80M | $53.13M |
| Long-term debt | $51.62M | $51.47M |
| Total debt | $51.62M | $51.47M |
| Total liabilities | $142.21M | $131.80M |
| Shareholders' equity | $365.87M | $402.22M |
| Net debt | -$234.89M | -$285.29M |
| Shares outstanding | 56.32M | 54.72M |
| Cash flow statement | ||
| Operating cash flow | -$48.98M | -$99.21M |
| Capital expenditure | $9.36M | $4.41M |
| Free cash flow | -$58.34M | -$103.62M |
| Investing cash flow | -$9.36M | -$4.41M |
| Financing cash flow | $11.19M | $180.12M |
| Depreciation & amortization | $6.39M | $5.23M |
| Stock-based compensation | $47.60M | $31.84M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.